Differential regulation of sphingosine kinases 1 and 2 in lung injury.
Two mammalian sphingosine kinase (SphK) isoforms, SphK1 and SphK2, possess identical kinase domains but have distinct kinetic properties and subcellular localizations, suggesting each has one or more specific roles in sphingosine-1-phosphate (S1P) generation. Although both kinases use sphingosine as a substrate to generate S1P, the mechanisms controlling SphK activation and subsequent S1P generation during lung injury are not fully understood. In this study, we established a murine lung injury model to investigate LPS-induced lung injury in SphK1 knockout (SphK1(-/-)) and wild-type (WT) mice. We found that SphK1(-/-) mice were much more susceptible to LPS-induced lung injury compared with their WT counterparts, quantified by multiple parameters including cytokine induction. Intriguingly, overexpression of WT SphK1 delivered by adenoviral vector to the lungs protected SphK1(-/-) mice from lung injury and attenuated the severity of the response to LPS. However, adenoviral overexpression of a SphK1 kinase-dead mutant (SphKKD) in SphK1(-/-) mouse lungs further exacerbated the response to LPS as well as the extent of lung injury. WT SphK2 adenoviral overexpression also failed to provide protection and, in fact, augmented the degree of LPS-induced lung injury. This suggested that, in vascular injury, S1P generated by SphK2 activation plays a distinctly separate role compared with SphK1-dependent S1P generation and survival signaling. Microarray and real-time RT-PCR analysis of SphK1 and SphK2 expression levels during lung injury revealed that, in WT mice, LPS treatment caused significantly enhanced SphK1 expression ( approximately 5x) levels within 6 h, which declined back to baseline levels by 24 h posttreatment. In contrast, expression of SphK2 was gradually induced following LPS treatment and was elevated within 24 h. Collectively, our results for the first time demonstrate distinct functional roles of the two SphK isoforms in the regulation of LPS-induced lung injury.
Wadgaonkar
Raj
R
Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA. raj.wadgaonkar@downstate.edu
Patel
Vipul
V
Grinkina
Natalia
N
Romano
Carol
C
Liu
Jing
J
Zhao
Yutong
Y
Sammani
Saad
S
Garcia
Joe G N
JG
Natarajan
Viswanathan
V
D000256:Adenoviridae; D000818:Animals; D017353:Gene Deletion; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D018014:Gene Transfer Techniques; D008070:Lipopolysaccharides; D008168:Lung / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D055370:Lung Injury / Q000150:complications / Q000201:enzymology* / Q000473:pathology; D008246:Lysophospholipids / Q000008:administration & dosage / Q000096:biosynthesis / Q000494:pharmacology; D008565:Membrane Proteins / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D010744:Phosphoric Monoester Hydrolases / Q000378:metabolism; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D011014:Pneumonia / Q000150:complications / Q000201:enzymology / Q000473:pathology; D011654:Pulmonary Edema / Q000150:complications / Q000201:enzymology / Q000473:pathology; D013110:Sphingosine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000096:biosynthesis / Q000494:pharmacology; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis; D000099157:Sphingosine Kinase
D008070:Lipopolysaccharides; D008246:Lysophospholipids; D008565:Membrane Proteins; D010744:Phosphoric Monoester Hydrolases; D017853:Phosphotransferases (Alcohol Group Acceptor); D013110:Sphingosine; D014409:Tumor Necrosis Factor-alpha; D000099157:Sphingosine Kinase; C060506:sphingosine 1-phosphate; C401298:sphingosine-1-phosphate phosphatase